You are here: Industry Insights > AstraZeneca

News List

NCCN, AstraZeneca Announce Lung Cancer Projects americanpharmaceuticalreview
March 05, 2020
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced three research projects selected to receive funding to improve healthcare provider performance ...
Astrazeneca Completes Divestment Agreement with Atnahs americanpharmaceuticalreview
March 04, 2020
AstraZeneca has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol) ...
AstraZeneca sells hypertension medicines to Atnahs Pharma pharmaceutical-technology
March 03, 2020
AstraZeneca has divested global commercial rights to a total of five hypertension drugs to Atnahs Pharma for a consideration of $350m.
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer worldpharmanews
January 16, 2020
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted ...
AZ to take $100m hit from ending trial of CV drug Epanova pharmaceutical-technology
January 15, 2020
AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3 carboxylic acids) following a recommendation by an Independent Data Monitory Committee that the drug was unlikely to demonstrate cardiovascular (CV) benefit
FDA grants priority review for AstraZeneca’s Lynparza pharmaceutical-technology
January 15, 2020
The US Food and Drug Administration (FDA) has granted priority review for Lynparza (olaparib) in combination with bevacizumab to treat advanced ovarian cancer.
MiNA Therapeutics, AstraZeneca partner for metabolic diseases pharmaceutical-technology
January 13, 2020
UK-based MiNA Therapeutics has entered into a research collaboration agreement with AstraZeneca to assess small activating RNA (saRNA) molecules in metabolic diseases.
AstraZeneca’s Farxiga gets FDA priority review for heart failure with HFrEF pharmaceutical-business-review
January 09, 2020
AstraZeneca’s Farxiga (dapagliflozin) has been granted priority review from the US Food and Drug Administration (FDA) for a certain population of patients with heart failure.
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction worldpharmanews
January 07, 2020
AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failu
AstraZeneca secures FDA priority review for Farxiga pharmaceutical-technology
January 07, 2020
AstraZeneca has secured the US Food and Drug Administration (FDA) priority review for Farxiga (dapagliflozin) to treat heart failure with reduced ejection fraction (HFrEF).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page